regardless of promising clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant opposition from pharmacy benefit managers. These insurers are often https://diegofmvj812277.blogs100.com/42421736/company-s-vyndamax-faces-is-meeting-pbm-challenges-a-look-of-coverage-battles